INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...
TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, ...
1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...
Learn more about whether Arrowhead Pharmaceuticals, Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on ...
Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ...
Dr Peter Bloomfield, director of research at the Macular Society, reflects on research developments and the meaningful difference these innovations can make for patients ...
Stocktwits on MSN
Regeneron stock slips premarket even after Wall Street lifts targets on strong Q4 — what’s weighing on the stock?
Several Wall Street firms raised price targets on Regeneron after its Q4 results. ・Q4 revenue and non-GAAP earnings both ...
Sandoz, the global leader in affordable medicines, today announced the launch of Enzeevu® (aflibercept) in Canada, its first ophthalmology biosimilar, expanding access to affordable treatment options ...
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar ...
Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Jay Bradner, Murdo Gordon ...
In addition to demonstrating that the vision gains and anatomic achievements or improvements with EYLEA HD over two years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results